Roflumilast

(Daliresp®)

Daliresp®

Drug updated on 11/16/2023

Dosage FormTablet (oral; 250 mcg, 500 mcg)
Drug ClassSelective phosphodiesterase 4 inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

Product Monograph / Prescribing Information

Document TitleYearSource
Daliresp (roflumilast) Prescribing Information. 2020AstraZeneca Pharmaceuticals LP, Wilmington, DE

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease.2023Global Initiative for Chronic Obstructive Lung Disease
Pocket guide to COPD Diagnosis, Management, and Prevention.2023Global Initiative for Chronic Obstructive Lung Disease
2023 Canadian Thoracic Society Guideline on Pharmacotherapy in Patients with Stable COPD.2023Canadian Journal of Respiratory, Critical Care, and Sleep Medicine
Global strategy for prevention, diagnosis and management of COPD. 2021Global Initiative for Chronic Obstructive Lung Disease
Global initiative for chronic obstructive lung disease: pocket guide to COPD.2021Global Initiative for Chronic Obstructive Lung Disease
Canadian Thoracic Society clinical practice guideline on pharmacotherapy in patients with COPD – 2019 update of evidence.2019Canadian Journal of Respiratory, Critical Care, and Sleep Medicine